NCT05276310 2026-04-21
A Study of IMC-002 in Patients With Advanced Cancer Failed to Standard Therapy
ImmuneOncia Therapeutics Inc.
Phase 1 Recruiting
ImmuneOncia Therapeutics Inc.
University of Rochester
Weill Medical College of Cornell University
Shanghai Allink Biotherapeutics Co., Ltd.
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Cancer Commons
Singapore General Hospital
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Suzhou Transcenta Therapeutics Co., Ltd.
NYU Langone Health
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Anwita Biosciences
HC Biopharma Inc.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.